BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30664251)

  • 1. Insight on mutation-induced resistance to anaplastic lymphoma kinase inhibitor ceritinib from molecular dynamics simulations.
    He MY; Li WK; Meiler J; Zheng QC; Zhang HX
    Biopolymers; 2019 Feb; 110(2):e23257. PubMed ID: 30664251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular dynamics simulations reveal the allosteric effect of F1174C resistance mutation to ceritinib in ALK-associated lung cancer.
    Ni Z; Wang X; Zhang T; Jin RZ
    Comput Biol Chem; 2016 Dec; 65():54-60. PubMed ID: 27764703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer.
    Ni Z; Zhang TC
    J Mol Model; 2015 Jul; 21(7):175. PubMed ID: 26084268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Mechanism Behind the Resistance of the G1202R-Mutated Anaplastic Lymphoma Kinase to the Approved Drug Ceritinib.
    Chen C; He Z; Xie D; Zheng L; Zhao T; Zhang X; Cheng D
    J Phys Chem B; 2018 May; 122(17):4680-4692. PubMed ID: 29648831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for drug resistance mechanisms against anaplastic lymphoma kinase.
    Goyal S; Jamal S; Shanker A; Grover A
    J Cell Biochem; 2019 Jan; 120(1):768-777. PubMed ID: 30161279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib.
    Zhu VW; Cui JJ; Fernandez-Rocha M; Schrock AB; Ali SM; Ou SI
    Lung Cancer; 2017 Aug; 110():32-34. PubMed ID: 28676215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.
    Guan J; Fransson S; Siaw JT; Treis D; Van den Eynden J; Chand D; Umapathy G; Ruuth K; Svenberg P; Wessman S; Shamikh A; Jacobsson H; Gordon L; Stenman J; Svensson PJ; Hansson M; Larsson E; Martinsson T; Palmer RH; Kogner P; Hallberg B
    Cold Spring Harb Mol Case Stud; 2018 Aug; 4(4):. PubMed ID: 29907598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role and targeting of anaplastic lymphoma kinase in cancer.
    Della Corte CM; Viscardi G; Di Liello R; Fasano M; Martinelli E; Troiani T; Ciardiello F; Morgillo F
    Mol Cancer; 2018 Feb; 17(1):30. PubMed ID: 29455642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K; Kolesar JM
    Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A molecular dynamics investigation into the mechanisms of alectinib resistance of three ALK mutants.
    He M; Li W; Zheng Q; Zhang H
    J Cell Biochem; 2018 Jul; 119(7):5332-5342. PubMed ID: 29323742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformational Transition of Key Structural Features Involved in Activation of ALK Induced by Two Neuroblastoma Mutations and ATP Binding: Insight from Accelerated Molecular Dynamics Simulations.
    He MY; Li WK; Zheng QC; Zhang HX
    ACS Chem Neurosci; 2018 Jul; 9(7):1783-1792. PubMed ID: 29638111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revealing Acquired Resistance Mechanisms of Kinase-Targeted Drugs Using an on-the-Fly, Function-Site Interaction Fingerprint Approach.
    Zhao Z; Bourne PE
    J Chem Theory Comput; 2020 May; 16(5):3152-3161. PubMed ID: 32283024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceritinib Treatment for Carcinomatous Meningitis with a Secondary Mutation at I1171T in Anaplastic Lymphoma Kinase.
    Ashinuma H; Shingyoji M; Hasegawa Y; Yokoi S; Yoshida Y
    Intern Med; 2018 Nov; 57(21):3153-3155. PubMed ID: 29877262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.
    Kodityal S; Elvin JA; Squillace R; Agarwal N; Miller VA; Ali SM; Klempner SJ; Ou SH
    Lung Cancer; 2016 Feb; 92():19-21. PubMed ID: 26775591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
    Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
    Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
    Califano R; Greystoke A; Lal R; Thompson J; Popat S
    Lung Cancer; 2017 Sep; 111():51-58. PubMed ID: 28838397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib.
    De Pas T; Pala L; Catania C; Conforti F
    Future Oncol; 2017 Dec; 13(29):2629-2644. PubMed ID: 28891712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
    Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ
    Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
    Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
    Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.